#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rheumatoid arthritis Synovial sarcoma Skin cancer Dupuytren's contracture Peripheral primitive neuroectodermal tumour of soft tissue Emphysema Cholangiosarcoma Pyruvate dehydrogenase complex deficiency Malignant melanoma Non-small cell lung cancer recurrent Ocular myasthenia Thyroid cancer metastatic Rosai-Dorfman syndrome Acute myeloid leukaemia Brain abscess More trials…

    Learn about Rare Diseases

    Rosai-Dorfman syndrome – Life with Disease Choroid melanoma – Life with Disease Ewing’s sarcoma – Treatment Ornithine transcarbamoylase deficiency – Basic Information Alport’s syndrome – Treatment Atypical teratoid/rhabdoid tumour of CNS – Treatment Glomerulonephritis membranous – Treatment Ewing’s sarcoma metastatic – Basic Information Congenital nephrogenic diabetes insipidus Carcinoid syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sonelokimab Bimekizumab ZIMISLECEL Fluorodopa (18F) Inclisiran Latozinemab Lebrikizumab Eptinezumab Riociguat Tipiracil Melphalan Ziftomenib Nalbuphine Hydrochloride Iph6501 Fluocinolone Acetonide Peposertib Treprostinil Clemastine Fumarate Crizotinib Dexrazoxane More therapies…

    Learn about Your Condition

    Stem cell transplant Glaucoma Thyroid mass Ventricular tachycardia Pulmonary vascular disorder Nicotine dependence Ocular lymphoma Eczema Liver transplant Bile acid synthesis disorder Noninfective chorioretinitis Ovarian cancer metastatic Stress Uveal melanoma Retinal neovascularisation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hepatocellular carcinoma

  • A Phase II Study of Cadonilimab Plus Lenvatinib Versus Lenvatinib in Advanced Hepatocellular Carcinoma After Atezolizumab/Bevacizumab Progression

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Lenvatinib
    France Italy Poland Spain

  • Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hepatobiliary cancer
    • Hepatocellular carcinoma
    • Cervix carcinoma
    France Ireland Italy Romania Spain

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    3 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    • Oesophageal squamous cell carcinoma
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Belzutifan
    • Lenvatinib
    Belgium Czechia Denmark Finland France Germany +4

  • A study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Ipilimumab
    France Germany Italy Poland Spain

  • A study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Hyaluronidase (Human Recombinant)
    • Tremelimumab
    • Durvalumab
    Poland

  • A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed

    Recruiting

    2 1 1
    Investigated Drugs:
    • VISUGROMAB
    • Lenvatinib
    • Nivolumab
    France Germany Italy Spain
1 2 3 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!